Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccinationArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 진단, 치료기술, 치료제, [키워드] Anti-spike Antibody Response B cell B cell responses BBIBP-CorV booster booster vaccination CD4 CD8 comparable COVID-19 COVID-19 vaccines de novo demonstrated detectable dramatic increase Epidemic exhibited Features humoral immune response Humoral immunity humoral responses interferon-γ Neutralizing antibodies omicron remained S protein SARS-CoV-2 SARS-COV-2 infection serotype Severe case Shanghai significantly T cell T cell response T cell responses T cell responses. Th1 cytokine vaccination vaccinee vaccinees wild type [DOI] 10.1080/22221751.2022.2130101 PMC 바로가기
COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia말레이시아에서 BNT162b2 백신을 접종한 의료 종사자의 COVID-19 획기적인 감염 및 체액성 면역 반응Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] 95% CI affected age Anti-S1 Anti-spike antibody Antibody Response antibody titres association Asymptomatic Asymptomatic individuals blood sample Blood samples BNT162b2 booster vaccination breakthrough Breakthrough infection breakthrough infections collected COVID-19 COVID-19 infection delta variant detectable domain geometric mean geometric mean titre GMT HCWs healthcare healthcare worker Healthcare workers humoral humoral immune response Humoral immunity IgG IgG assay individual individuals Infection investigated Malaysia not different notable outcome Participants prospective cohort study Protein response significantly significantly higher Support symptomatic the antibody response vaccination Vaccine vaccine doses vaccine. waned was measured [DOI] 10.1080/22221751.2022.2065936 PMC 바로가기 [Article Type] Article
Can torque teno virus be a predictor of SARS-CoV-2 disease progression in cancer patients?Article Published on 2022-12-012022-11-15 Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), SARS, 치료기술, [키워드] analysed association Can Cancer cancer patient Cancer patients clinical manifestation Control control subjects controls correlation COVID-19 death deficiency demonstrated detectable died DNA immune system indicated Infection Nasopharyngeal swab outcomes patients with SARS-CoV-2 previous study progression Retrospective study SARS-CoV-2 SARS-CoV-2 disease SARS-CoV-2 RNA SARS-CoV-2-positive patients significantly lower statistically significant subjects survival rate torque Torque teno virus. Viral load virus was related [DOI] 10.1016/j.jiac.2022.08.015 PMC 바로가기
Saliva as a Potential Specimen to Monitor IL-6, TNF-α and IL-10 in COVID-19 PatientsArticle Published on 2022-12-012022-11-15 Journal: Inflammation [Category] COVID19(2023년), SARS, 치료기술, [키워드] alleviate Blood blood specimen Clinical prognosis collected comparable COVID-19 COVID-19 patients cycle threshold detectable elevated elicited enrolled expressed expression human saliva IL-10 IL-10. IL-6 inclusion criteria Infection Inflammation Inflammation. Inflammatory Inflammatory cytokine inflammatory gene Lung injury marker MINI Mortality Patient pilot study Potential protocols Qiagen RNA RT-PCR Saliva SARS-CoV-2 severe cases specimen subject the mean TNF-α were assessed [DOI] 10.1007/s10753-022-01698-x PMC 바로가기
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Article Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome Beta Blood caused clinically Concentration coronavirus COVID-19 creatine phosphokinase CT-P63 deaths declining Delta demonstrated detectable dose double-blind evaluated groups healthy volunteer Immunity in vitro in vivo Infection Infectious virus lung monoclonal monoclonal antibody morbidity and mortality mutated variant Neutralizing Neutralizing activity neutralizing antibody neutralizing antibody. omicron pandemic parallel-group participant peaked phase Placebo placebo-controlled Preclinical prevalent Prophylactic Randomized reduced respiratory tract Safe SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants of concern Serious Adverse Events significantly single ascending dose study drug TEAE titre Tolerability Transgenic mouse treated Treatment treatment-emergent adverse event vaccination variants variants of SARS-CoV-2 wild-type [DOI] 10.1080/22221751.2022.2117094 PMC 바로가기
The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variantsCoronVac 백신 3차 접종은 SARS-CoV-2 Delta 및 Omicron 변이체를 인식하는 광범위하고 강력한 적응 면역 반응 유도Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive Adaptive immune response B cell B cells boost booster booster dose booster vaccination CD4 CD8 Cell circulating comparable contagious CoronaVac coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine Delta demonstrated detectable domain dose effective elevated elicited fold follicular healthy subject helper T cell Humoral immunity IgA responses immune responses Inactivated vaccine individual induce memory B memory B cell memory B cells neutralization neutralization activities neutralization activity neutralization. neutralizing activities omicron Omicron variants peaked predominant preserved Protein RBD receiving recognize reduced remained respiratory response SARS-CoV-2 SARS-CoV-2 delta SARS-CoV-2 variant significantly increased spike-specific IgG strain subpopulations sustained T cell T cell responses T cells T cells response vaccination variant variants VOCs [DOI] 10.1080/22221751.2022.2081614 PMC 바로가기 [Article Type] Article
Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection: A prospective cohort studyArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome antibody asymptomatic infections benefit blood sample booster dose Clinical severity collected coronavirus coronavirus disease COVID-19 COVID-19 vaccination detectable dose evaluated Evidence first dose humoral humoral immune response Humoral immunity Humoral response inactivated Inactivated COVID-19 vaccine individual individuals infected individuals Infection median mild cases moderate multicenter NAb titer NAbs naïve individual naïve individuals natural infection Neutralizing Neutralizing activity neutralizing antibody omicron pan-immunoglobulins. participant prospective cohort study Protein receive recovered patient SARS-CoV-2 second dose seroconversion rate severity significantly single dose single vaccine the vaccine U/mL vaccination variant [DOI] 10.1002/jmv.28055 PMC 바로가기
Peptide microarrays coupled to machine learning reveal individual epitopes from human antibody responses with neutralizing capabilities against SARS-CoV-2기계 학습과 결합된 펩티드 마이크로어레이는 SARS-CoV-2에 대한 중화 기능을 가진 인간 항체 반응의 개별 에피토프를 나타냅니다.Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 진단, 치료기술, 치료법, [키워드] anti-SARS-CoV-2 antibody Antibody binding assays binding epitope capture causative agent cellular coronavirus coronavirus SARS-CoV-2 Course COVID-19 detectable epitope Epitopes human antibody response IgA IgG IgM antibody immunoassays incubated infected with SARS-CoV-2 machine learning Microarray N-terminus negative control samples neutralization neutralization assays Neutralizing Neutralizing antibodies nine overlapping Patient peptide peptide arrays peptides positive protective effect Protective effects random Random forest response S protein SARS CoV SARS CoV-2 SARS-CoV-2 sera serology Serology. Specific structural protein structural proteins the disease the S protein vaccine candidate vaccine candidates Viral [DOI] 10.1080/22221751.2022.2057874 PMC 바로가기 [Article Type] Article
Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccinesCOVID-19 백신 접종 후 면역 장수: 현재 승인된 백신에 대한 종합 검토Review Published on 2022-11-302022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, 진단, [키워드] Ad26.COV2.S anti-Spike IgG antibody antibody persistence approved Asymptomatic AZD1222 BNT162b1 BNT162b2 BNT162b2 vaccine BNT162b2 vaccines booster dose Cell-mediated immunity COVID-19 COVID-19 vaccination detectable first dose Humoral immunity IgA antibodies immune response Immunity immunogenicity induce long-term immunity Long-term protection Longevity mRNA-1273 mRNA-1273 vaccine neutralizing effect peaked persistence Perspective produced provide SARS-CoV-2 Spread systematic review T-cell T-cell immunity T-cell Response Vaccine Vaccines. [DOI] 10.1080/21645515.2022.2037384 PMC 바로가기 [Article Type] Review
Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamstersArticle Published on 2022-11-042022-11-15 Journal: Nature Communications [Category] SARS, 변종, 진단, 치료기술, [키워드] Antigen B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 Beta block Community COVID-19 vaccine current Delta delta variant detectable Efficacy eliminating expressed Fever Gamma hamster immunization Lineage Lung pathology maintain Neutralizing antibody response omicron P.1 pandemic predominant Prevent PROTECT SARS-CoV-2 strains SARS-CoV-2 variant sequence Spread titre Transmission Vaccine variants variants of concern vectored vaccine virus VoC VOCs [DOI] 10.1038/s41467-022-34439-7 PMC 바로가기